Physician profile
Daniel Lynch
NPI 1174071575
$2,153.21
in general payments reported to CMS, 2019-2025
30 companies · $665 in 2025
The $665 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $13.04 · 2023: $448 · 2024: $771 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $405.12 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $221.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $193.42 | 2021-2025 | |
| Novo Nordisk INC | $192.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $165.24 | 2023-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $137.81 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $124.88 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Pfizer INC. | $100.40 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.12 | 2023-2025 | Rexulti |
| Abbott Laboratories | $48.43 | 2023-2024 | Proclaim |
| Lundbeck LLC | $47.50 | 2023-2024 | Rexulti, Vyepti |
| Amgen INC. | $44.53 | 2024-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.46 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.97 | 2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $34.97 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $33.88 | 2021-2025 | Tirosint, Flector, Licart |
| Ucb, INC. | $29.83 | 2021 | |
| Inspire Medical Systems, INC. | $22.82 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $19.55 | 2025 | Spravato |
| Sumitomo Pharma America, INC. | $18.42 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $16.98 | 2023 | Quviviq |
| Almatica Pharma LLC | $16.30 | 2024 | Teriparatide, Loreev Xr |
| Organon LLC | $15.35 | 2024 | |
| Merck Sharp & Dohme LLC | $14.28 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Eisai INC. | $14.19 | 2021 | |
| Astellas Pharma US INC | $13.94 | 2021 | |
| Amarin Pharma, INC. | $13.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.13 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.04 | 2022 | |
| Adlon Therapeutics L.P. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.